Investigational drug · Phase 3
ipilimumab and nivolumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
613
Any phase or sponsor naming "ipilimumab and nivolumab"
First trial start
2025
Aug 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ipilimumab and nivolumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma (Skin Cancer)
- Melanoma Stage IIIB-IV
- Cutaneous Melanoma
- Unresectable Melanoma
Approved drugs for the same conditions: Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ipilimumab and nivolumab" as an intervention, largest first.
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT04294771 · 500,000 participants (planned) · Start Jan 1, 2019 · Primary completion Jan 1, 2030
Drug: ICI · For: Myocarditis; Cardiomyopathies; Heart Diseases and 3 more
Sites: Paris, France
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT05934214 · 141,630 participants · Start Jan 1, 2023 · Primary completion Dec 31, 2023
Drug: Immune checkpoint inhibitor · For: Cancer; Immune-related Adverse Event; Immune Checkpoint Inhibitor-Related Myocarditis
Sites: Paris, France · 2 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
Johns Hopkins UniversityAcademic, hospital or other
NCT04898751 · 2,214 participants · Start Jan 1, 2008 · Primary completion Aug 31, 2020
Drug: Immune checkpoint inhibitor (ICI) · For: Cutaneous Toxicity From ICI Therapy
Sites: Baltimore, Maryland
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02872116 · 2,031 participants · Start Oct 12, 2016 · Primary completion May 27, 2020
Drug: Nivolumab; Ipilimumab and 4 more · For: Gastric Cancer; Gastroesophageal Junction Cancer; Esophageal Adenocarcinoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 179 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05611229 · 1,975 participants · Start Jun 16, 2020 · Primary completion Dec 3, 2021
Drug: Nivolumab; Pembrolizumab · For: Metastatic Melanoma
Sites: East Hanover, New Jersey
SWOG Cancer Research NetworkResearch network
NCT02154490 · 1,864 participants · Start Jul 8, 2014 · Primary completion Apr 1, 2022
Drug: Docetaxel; Durvalumab and 9 more · For: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,004 sites in all
- An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03068455 · 1,844 participants · Start Apr 11, 2017 · Primary completion Jun 12, 2020
Drug: nivolumab; ipilimumab · For: Melanoma
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 124 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03165409 · 1,828 participants · Start Feb 27, 2017 · Primary completion Sep 30, 2017
Drug: Nivolumab; Ipilimumab · For: Melanoma
Sites: Princeton, New Jersey
Newest research
PubMed records naming it or its code names, newest first.
- 10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience.
Javaid A, Peres T, Schmitt AM, et al. · Int J Cancer 2027
- B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma.
Dhodapkar KM, Matera A, Duffy AM, et al. · J Clin Invest 2026
- The Relationship Between Pre-Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer.
Zielhuis SWJ, de Jong KAM, Huisman-Siebinga H, et al. · Clin Transl Sci 2026
- Giant cutaneous melanoma of the abdominal wall: a case report.
Tziova A, Kunjko K, Adamčevik S · Int J Surg Case Rep 2026
- Incidence, severity and potential pathomechanism of immune-related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy.
Roggo A, Ivanovic N, Turko P, et al. · J Dtsch Dermatol Ges 2026
- Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.
Chalabi M, van den Dungen LDW, de Gooyer PGM, et al. · Lancet 2026
Also in development for Melanoma (Skin Cancer)
- LNS8801Phase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- nivolumab and relatlimabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.